پذیرفته شده و در حال انتشار
برگشت به فهرست مقالات |
برگشت به فهرست نسخه ها
چکیده: (124 مشاهده)
Background: Differentiating Prostate Cancer (PC) from benign prostatic hyperplasia (BPH) remains clinically challenging due to overlapping symptoms and biomarker alterations. This study compared biochemical, hematological, and inflammatory markers in both conditions to assess their potential diagnostic value.
Methods: A cross-sectional study was performed on 40 patients with PC and 120 patients with benign prostatic hyperplasia. The measurement of biochemical parameters included complete blood count, C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) and total and free prostate-specific antigen (PSA). The process involved statistical comparisons, ROC analysis, and correlation tests
Results: Compared to BPH, patients with PC had significantly higher PSA (free and total), CRP, and lymphocyte counts (All p<0.05). Despite the diagnostic utility of PSA and inflammatory markers (AUCs 0.68-0.80), hematological parameters in isolation were not strong discriminators (AUCs<0.50), and a combined biomarker strategy would be more effective in clinical discrimination.
Conclusion: Detection of PC from BPH is accurately achieved by examining elevated free and total PSA levels, along with increased systemic inflammation, as indicated by CRP. The independent discriminant value of hematologic parameters is limited despite significant diversity between groups.. A combination of PSA and inflammatory markers in a two-biomarker strategy can improve clinical discrimination and reduce inappropriate therapy.
Methods: A cross-sectional study was performed on 40 patients with PC and 120 patients with benign prostatic hyperplasia. The measurement of biochemical parameters included complete blood count, C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) and total and free prostate-specific antigen (PSA). The process involved statistical comparisons, ROC analysis, and correlation tests
Results: Compared to BPH, patients with PC had significantly higher PSA (free and total), CRP, and lymphocyte counts (All p<0.05). Despite the diagnostic utility of PSA and inflammatory markers (AUCs 0.68-0.80), hematological parameters in isolation were not strong discriminators (AUCs<0.50), and a combined biomarker strategy would be more effective in clinical discrimination.
Conclusion: Detection of PC from BPH is accurately achieved by examining elevated free and total PSA levels, along with increased systemic inflammation, as indicated by CRP. The independent discriminant value of hematologic parameters is limited despite significant diversity between groups.. A combination of PSA and inflammatory markers in a two-biomarker strategy can improve clinical discrimination and reduce inappropriate therapy.
| بازنشر اطلاعات | |
 |
این مقاله تحت شرایط Creative Commons Attribution-NonCommercial 4.0 International License قابل بازنشر است. |